Daix (France), Long Island City (New York, United States), March 22, 2024 -
Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies for the
treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known
as non-alcoholic steatohepatitis (NASH), and other diseases with significant
unmet medical needs, today announced that its management team will host a
webcast to present the Company's 2023 full-year financial results on Thursday,
March 28, 2024.
Inventiva's 2023 full-year financial results will be published on Wednesday,
March 27, 2024 at 4:00 pm (New York), 9:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief
Scientific Officer and cofounder of Inventiva, and Jean Volatier, Chief
Financial Officer of Inventiva, will hold a conference call in English, followed
by a Q&A session, on Thursday, March 28, 2024, at 8:00 am (New York), 1:00 pm
(Paris).
The conference call and the slides of the presentation will be webcast live at:
https://edge.media-server.com/mmc/p/eh78kegs and also available on Inventiva's
website in the "Investors - Financial results
(https://inventivapharma.com/investors/financial-results-presentations/)"
section.
In order to receive the conference access information necessary to join the
conference call, it is required to register in advance using the following link:
https://register.vevent.com/register/BIca56dabf4edf46ecaaca0e735626f044.
Participants will need to use the conference access information provided in the
e-mail received at the point of registering (dial-in number and access code).
A replay of the conference call and the presentation will be available after the
event at: http://inventivapharma.com/investors/financial-results-presentations/.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research
and development of oral small molecule therapies for the treatment of patients
with MASH/NASH, and other diseases with significant unmet medical need. The
Company benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and epigenetic
modulation. Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other development
opportunities to add to its pipeline.
Inventiva's lead product candidate, lanifibranor, is currently in a pivotal
Phase III clinical trial, NATiV3, for the treatment of adult patients with
MASH/NASH, a common and progressive chronic liver disease for which there are
currently no approved therapies.
Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment
of adult MPS VI patients. As part of Inventiva's decision to focus clinical
efforts on the development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with respect to its
potential further development. Inventiva is also in the process of selecting a
candidate for its Hippo signaling pathway program.
The Company has a scientific team of approximately 90 people with deep expertise
in the fields of biology, medicinal and computational chemistry,
pharmacokinetics and pharmacology, and clinical development. It owns an
extensive library of approximately 240,000 pharmacologically relevant molecules,
approximately 60% of which are proprietary, as well as a wholly-owned research
and development facility.
Inventiva is a public company listed on compartment B of the regulated market of
Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market
in the United States (ticker: IVA). www.inventivapharma.com
(http://www.inventivapharma.com/)
Contacts
Brunswick Group
Tristan Roquet Montegon Westwicke, an ICR
Inventiva / Company
Aude Lepreux / Patricia L. Bank
Pascaline Clerc Julia Cailleteau Investor relations
EVP, Strategy and Media relations patti.bank@westwicke.c
Corporate Affairs inventiva@brunswickgrou om
media@inventivaphar p.com (mailto:patti.bank@wes
ma.com (mailto:inventiva@bruns twicke.com)
(mailto:media@inven wickgroup.com)
tivapharma.com) +1
+1 202 499 8937 +33 1 53 96 83 83 415 513-1284Â